GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Q BioMed Inc (OTCPK:QBIO) » Definitions » Interest Coverage

Q BioMed (Q BioMed) Interest Coverage : 0 (At Loss) (As of Feb. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Q BioMed Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Q BioMed's Operating Income for the three months ended in Feb. 2023 was $-0.45 Mil. Q BioMed's Interest Expense for the three months ended in Feb. 2023 was $-0.28 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Q BioMed's Interest Coverage or its related term are showing as below:


QBIO's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 145.09
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Q BioMed Interest Coverage Historical Data

The historical data trend for Q BioMed's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Q BioMed Interest Coverage Chart

Q BioMed Annual Data
Trend Nov13 Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22
Interest Coverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Q BioMed Quarterly Data
May18 Aug18 Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Q BioMed's Interest Coverage

For the Biotechnology subindustry, Q BioMed's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Q BioMed's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Q BioMed's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Q BioMed's Interest Coverage falls into.



Q BioMed Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Q BioMed's Interest Coverage for the fiscal year that ended in Nov. 2022 is calculated as

Here, for the fiscal year that ended in Nov. 2022, Q BioMed's Interest Expense was $-1.38 Mil. Its Operating Income was $-3.45 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Q BioMed did not have earnings to cover the interest expense.

Q BioMed's Interest Coverage for the quarter that ended in Feb. 2023 is calculated as

Here, for the three months ended in Feb. 2023, Q BioMed's Interest Expense was $-0.28 Mil. Its Operating Income was $-0.45 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Q BioMed did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Q BioMed  (OTCPK:QBIO) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Q BioMed Interest Coverage Related Terms

Thank you for viewing the detailed overview of Q BioMed's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Q BioMed (Q BioMed) Business Description

Traded in Other Exchanges
N/A
Address
C/o Ortoli Rosenstadt LLP, 366 Madison Avenue, 3rd Floor, New York, NY, USA, 10017
Q BioMed Inc is a biomedical acceleration and development company. It has a focus on licensing, acquiring, and providing strategic resources to life sciences and healthcare companies. The company intends to mitigate risk by acquiring multiple assets over time and across a broad spectrum of healthcare-related products, companies, and sectors. Generic Strontium Chloride Sr-89 Injection USP (Strontium-89) is a radioactive pharmaceutical injection to relieve bone pain in patients with painful skeletal metastases. It also has three development-stage products: QBM-001 for rare pediatric non-verbal autism spectrum disorder, Uttroside-B for liver cancer, and MAN 01 for glaucoma.
Executives
William S Rosenstadt director, 10 percent owner, officer: Chief Legal Officer ORTOLI ROSENSTADT LLP, 501 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10022
Denis Corin director, 10 percent owner, officer: Chief Executive Officer 10 MARKET STREET, SUITE 427, GRAND CAYMAN E9 KY1-9006
Rick Panicucci director 501 MADISON STREET, 14TH FLOOR, NEW YORK NY 10022
Alan P Lindsay 10 percent owner 580 HORNBY STREET, FIFTH FLOOR, VANCOUVER BC CANADA V6C 2E7 A1